Skip to main content

Table 3 Association between final outcomes to treatment (change in VA/CMT) and choroidal thickness/presence of pachyvessels

From: Polypoidal choroidal vasculopathy—characteristics and response to treatment with bevacizumab in caucasian patients

 

pachyvessels

Choroidal thickness above/bellow 250 µ

Choroidal thickness above/bellow 300 µ

Change in VA between beginning and final follow up (LogMar)

No

− 0.20 ± 0.77

(P = 0.097)

 < 250 µ

− 0.04 ± 0.65

(P = 0.44)

 < 300 µ

− 0.002 ± 0.50

(P = 0.68)

Yes

− 0.09 ± 0.39

(p = 0.097)

 > 250 µ

− 0.08 ± 0.37

(P = 0.44)

 > 300 µ

− 0.1 ± 0.5

(P = 0.68)

Change in CMT between beginning and final follow up (µ)

No

− 126.36 ± 140 (P = 0.54)

 < 250 µ

− 81.9 ± 143.2(P = 0.29)

 < 300 µ

− 92.3 ± 133.5(P = 0.25)

Yes

− 96.18 ± 139.3 (P = 0.54)

 > 250 µ

− 126.9 ± 133.2(P = 0.29)

 > 300 µ

− 154.5 ± 158.4(P = 0.25)

  1. The bold values are patient without pachyvessels